A 35-year old woman, who developed a deep wound in her abdomen while undergoing radiation therapy for cancer, was successfully treated using a new stem cell therapy at a hospital here.
Neelam, a mother of two, kept ignoring the fat deposit in her abdomen, thinking it was a regular feature for every married woman.
However, she soon had to visit a doctor after a lump surfaced on her abdomen as the fat deposit grew.
Doctors performed a surgery in which the lump was removed. However, Neelam was told that the lump was cancerous and she needed to undergo complete cancer treatment as there were chances of recurrence.
However, as radiation therapy started, Neelam developed a deep burn wound on her abdomen.
Such was the condition of the wound that doctors had to stop the therapy and she was asked to undergo another treatment for healing the wound, which started oozing white discharge that had a foul smell.
More From This Section
As there were not many experts to treat a wound created by radiation therapy, Neelam was advised about Human Embryonic Stem Cell (HESC) therapy and that Geeta Shroff was an expert in this new field.
After consulting Shroff, Neelam started undergoing HESC therapy, and was completely cured in three weeks following which she could continue her cancer treatment.
Explaining about HESC therapy, Shroff said: "The therapy involves injecting isolated human embryonic stem cells into patients to help their body heal on its own in a natural way."
"The stem cell on entering the body engrafts in the appropriate tissue and supplements replacement or repair of the missing function of the body. The therapy has no known side effects," she said.
Shroff, who has spent several years researching the benefits of HESC, said the therapy can be used for curing several other health problems such as spinal disorders.
Shroff, who said she has treated over 1,300 patients so far with no side effects, has over 15 research papers published in journals in different parts of the world.
She has multiple patents in 65 countries, including the US, Singapore, Japan, Australia and New Zealand, regarding the technology and its therapeutic application.